"ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic ...

(Reuters) -AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that the ...

The endometrial cancer market space will experience significant growth during the forecast period of 2025--2034. The future is brighter for patients with endometrial cancer. Targeted agents and ...

Detailed price information for Daiichi Sankyo Ltd (DSKYF) from The Globe and Mail including charting and trades.

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed with ...

The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating Enhertu plus pembrolizumab versus pembrolizumab, platinum-based ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have received priority review from the FDA for their supplemental marketing application for Enhertu in combination with pertuzumab, marketed by Roche (OTCQX ...

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

AstraZeneca and Daiichi Sankyo's Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that the ...